Table 3 Comparative overview of the literature focusing on brachytherapy boost for anal canal carcinoma according to the brachytherapy dose-rate
From: Interstitial high-dose rate brachytherapy as boost for anal canal cancer
Authors (Year) | # pts* | Median FU (months) | Dose Rate | Median BT dose (Gy) | LR (%) | OS (%) | Colostomy | Late toxicity ≥ G3 [%] | ||
|---|---|---|---|---|---|---|---|---|---|---|
LRR (%) | LCR (%) | CR % | CFS % | |||||||
Peiffert et al. (1997) [16] | 101/118 | 72 | LDR | 21.5 | N/A | 60 (5 y) | 9 | - | 13.5 | |
Papillon et al. (1989) [17] | 221 | > 36 | LDR | 20 to 30 | N/A | 69.2 (3 y) | 2.7 | - | N/A | |
Wagner et al. (1994) [18] | 96 | 35.5 to 51.7** | LDR | 20.2** | 16.6 | - | 64 (5 y) | N/A | 9.25 | |
Gerard et al. (1999) [19] | 19 | N/A | PDR | 10 to 25 | 5,2 | - | 100 (1 y) | 0 | - | 0 |
Bruna et al. (2006) [20] | 71 | 28.5 | PDR | 17.8** | N/A | 90 (2y) | - | 89 (2 y) | N/A | |
Roed et al. (1996) [10] | 17 | 11.3 | PDR | 28.85 | 23.5 | - | N/A | 47 | - | N/A |
Kapp et al. (2001) [21] | 39 | 31 | HDR | 6 to 12*** | 81 (3 y) | 80 (3 y DSS) | - | 78 (3 y) | 7.6 | |
76 (5 y) | 76 (5 y DSS) | 73 (5 y) | ||||||||
Vordermark et al. (2001) [5] | 20 | 52.8** | HDR | 5 to 12 | 5 | - | 84 (5 y) | - | 68.9 (5 y) | N/A |
Doniec et al. (2006) [23] | 50 | 34 | HDR | 8 to 12 | N/A | 74 (5 y) | 4 | - | N/A | |
Oehler-Jänne et al. (2007) [24] | 34 | 60** | HDR | 14 | 10.3 (5y) | - | 66 (10 y) | 15 | - | N/A |
Saarilahti et al. (2008) [25] | 29/59 | 51 | HDR | 12 | N/A | N/A | N/A | N/A | ||
Kapoor et al. (2013) [15] | 16 | 41 | HDR | 18 (6f) | - | 87.5 (2 y) | N/A | N/A | 0 | |
21 (7f) | N/A | |||||||||
Falk et al. (2014) | 28 | 27.5 | HDR | 12 (3f) | - | 83 (2 y) | 87.7 | - | 75.1 (2 y) | 7.1 |